<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00705874</url>
  </required_header>
  <id_info>
    <org_study_id>47-01-002</org_study_id>
    <nct_id>NCT00705874</nct_id>
  </id_info>
  <brief_title>Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma</brief_title>
  <official_title>A Phase I Open Label, Multicenter, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Dose Limiting Toxicity, Safety and Pharmacokinetics of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Progen Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Progen Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will aims to determine the maximum tolerated dose of CGC-11047 when used in
      individual combinations with gemcitabine, or docetaxel, or bevacizumab, or erlotinib or
      cisplatin or 5-flurouracil or sunitinib in one of 7 treatment arms. The dose of CGC-11047
      will be escalated until the maximum tolerated dose is established.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will use a dose escalation design to determine the MTD of CGC-11047 when used in
      individual combinations with gemcitabine, or docetaxel, or bevacizumab, or erlotinib or
      cisplatin or 5-flurouracil or sunitinib in one of 7 treatment arms. The dose of CGC-11047
      will be escalated in cohorts of 3 patients and dose escalation can proceed in each treatment
      group independent of dose escalation in the other treatment groups. CGC-11047 will be
      administered IV over 60 minutes and the doses of gemcitabine, docetaxel, bevacizumab,
      cisplatin, 5-flurouracil or sunitinib will remain fixed according to their respective product
      labeling.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>End of Study</time_frame>
    <description>The MTD was defined as the dose below which one-third of at least 6 patients (2/6) experienced a dose limiting toxicity (DLT).
DLTs had to occur during cycle 1 of treatment and had to be considered related to PG-11047:
Any nonhematologic toxicity &gt; Grade 3 lasting &gt; 3 days
Grade 4 thrombocytopenia
Grade 4 Anemia on the next scheduled dosing day
Grade 4 Neutropenia (lasting &gt; than 5 days
Any febrile neutropenia (Grade 3 or 4))
Inability to receive all scheduled doses of PG-11047 during the first dosing cycle due to drug related toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug Safety</measure>
    <time_frame>Ongoing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>End of Study</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CGC-11047 in combination with Gemcitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CGC-11047 in combination with Docetaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CGC-11047 in combination with Bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CGC-11047 in combination with Erlotinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin: 80 mg/m2 administered IV over 1 hour once every 28 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CGC-11047 in combination with 5-Flurouracil / Leucovorin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CGC-11047 in combination with Sunitinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CGC-11047 and gemcitabine</intervention_name>
    <description>Gemcitabine: (Closed to enrollment) 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle. CGC-11047 will only be given on days 1 and 15 of each cycle and will start at dose level -1 (50 mg).</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CGC-11047 and docetaxel</intervention_name>
    <description>Docetaxel: (Closed to enrollment) 75 mg/m2 administered IV over 60 minutes every 21 days. CGC-11047 will be administered only on Day 1 of each 21-day cycle and will start at dose level -1 (50 mg).</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CGC-11047 and bevacizumab</intervention_name>
    <description>Bevacizumab: 5 mg/kg administered IV once every 14 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CGC-11047 and erlotinib</intervention_name>
    <description>Erlotinib: 150 mg taken orally every day of each 28-day cycle. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.</description>
    <arm_group_label>4</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CGC-11047 and cisplatin</intervention_name>
    <description>Cisplatin: 80 mg/m2 administered IV over 1 hour once every 28 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CGC-11047 and 5-flurouracil / leucovorin</intervention_name>
    <description>5-Flurouracil / Leucovorin: Leucovorin 500 mg/m2 IV over 2 hours with 5 - FU 500 mg/m2 IV bolus starting 1 hour into leucovorin infusion weekly for 6 wks, repeated every 56 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.</description>
    <arm_group_label>6</arm_group_label>
    <other_name>5-FU</other_name>
    <other_name>Florouracil</other_name>
    <other_name>Efudix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CGC-11047 and sunitinib</intervention_name>
    <description>Sunitinib: 50 mg orally once daily, 4 weeks on treatment followed by 2 weeks off (42 day cycle). CGC-11047 will be administered on Days 1 and 8 of a 21 day cycle.</description>
    <arm_group_label>7</arm_group_label>
    <other_name>Sutent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  non-hematological advanced solid tumor malignancy or lymphoma where no curative
             therapy exists in which monotherapy with gemcitabine or docetaxel or bevacizumab or
             erlotinib or cisplatin, or 5-flurouracil or sunitinib would otherwise be warranted.

          -  measurable disease based on radiographic evaluation or elevated tumor markers.

          -  ECOG - 0 or 1 (KPS &gt;70).

          -  Life expectancy &gt; 3 months.

        Exclusion Criteria:

          -  chemotherapy within 21 days or radiotherapy within 4 weeks prior to entering the study

          -  known active brain metastases or leptomeningeal carcinomatosis.

          -  history of a myocardial infarction within the prior 6 months or, hospitalizations for
             congestive heart failure within the prior 6 months, or active treatment for
             uncontrolled cardiac arrhythmias

          -  clinically significant gastrointestinal tract hemorrhage, requiring transfusion
             therapy, within the prior 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joe Stephenson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Centres of the Carolinas, Greenville, SC 29605</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centre</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centres of Florida</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Indiana Cancer Centres</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centres of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology PC</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayton Oncology and Hematology, PA</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centres of the Carolinas</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyler Cancer Centre</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Star Lodge Cancer Centre</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.progen.com.au</url>
    <description>Progen Pharmaceuticals website</description>
  </link>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2008</study_first_submitted>
  <study_first_submitted_qc>June 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2008</study_first_posted>
  <results_first_submitted>November 17, 2011</results_first_submitted>
  <results_first_submitted_qc>January 22, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 27, 2012</results_first_posted>
  <last_update_submitted>June 21, 2016</last_update_submitted>
  <last_update_submitted_qc>June 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>advanced cancer</keyword>
  <keyword>solid tumors</keyword>
  <keyword>lymphoma</keyword>
  <keyword>CGC-11047</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment period was June 2006 through March 2011, with last patient being treated May 2011. Patients were recruited through oncology clinics.</recruitment_details>
      <pre_assignment_details>There was no run-in phase. Patients were assigned to treatment arm based on their cancer type and which standard of care therapy was appropriate based on Investigatorsâ€™ discreation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PG11047/Gemcitabine</title>
          <description>PG-11047 (infusion on Days 1 and 15 of each cycle) in combination with Gemcitabine (1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle).</description>
        </group>
        <group group_id="P2">
          <title>PG11047/Docetaxel</title>
          <description>PG-11047 (infusion on Day 1 of each 21 day cycle) in combination with Docetaxel (75 mg/m2 administered IV over 60 minutes every 21 days).</description>
        </group>
        <group group_id="P3">
          <title>PG11047/Bevacizumab</title>
          <description>PG-11047 (infusion on Days 1, 8 and 15 of a 28 day cycle) in combination with Bevacizumab (5 mg/kg administered IV once every 14 days).</description>
        </group>
        <group group_id="P4">
          <title>PG11047/Erlotinib</title>
          <description>PG-11047 (infusion on Days 1, 8 and 15 of a 28 day cycle) in combination with Erlotinib (150 mg taken orally every day of each 28-day cycle).</description>
        </group>
        <group group_id="P5">
          <title>PG11047/Cisplatin</title>
          <description>Cisplatin: 80 mg/m2 administered IV over 1 hour once every 28 days. PG-11047 will be administered by infusion on Days 1, 8 and 15 of a 28 day cycle.</description>
        </group>
        <group group_id="P6">
          <title>PG11047/5-Flurouracil</title>
          <description>PG-11047 (infusion on Days 1, 8 and 15 of a 28 day cycle) in combination with 5-Flurouracil / Leucovorin (Leucovorin 500 mg/m2 IV over 2 hours with 5 - FU 500 mg/m2 IV bolus starting 1 hour into leucovorin infusion weekly for 6 weeks, repeated every 56 days).</description>
        </group>
        <group group_id="P7">
          <title>PG11047/Sunitinib</title>
          <description>PG-11047 (infusion on Days 1 and 8 of a 21 day cycle) in combination with Sunitinib (50 mg orally once daily, 4 weeks on treatment followed by 2 weeks off (42 day cycle)).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="34"/>
                <participants group_id="P4" count="34"/>
                <participants group_id="P5" count="48"/>
                <participants group_id="P6" count="32"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="33"/>
                <participants group_id="P5" count="36"/>
                <participants group_id="P6" count="28"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PG11047/Gemcitabine</title>
          <description>PG-11047 (infusion on Days 1 and 15 of each cycle) in combination with Gemcitabine (1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle).</description>
        </group>
        <group group_id="B2">
          <title>PG11047/Docetaxel</title>
          <description>PG-11047 (infusion on Day 1 of each 21 day cycle) in combination with Docetaxel (75 mg/m2 administered IV over 60 minutes every 21 days).</description>
        </group>
        <group group_id="B3">
          <title>PG11047/Bevacizumab</title>
          <description>PG-11047 (infusion on Days 1, 8 and 15 of a 28 day cycle) in combination with Bevacizumab (5 mg/kg administered IV once every 14 days).</description>
        </group>
        <group group_id="B4">
          <title>PG11047/Erlotinib</title>
          <description>PG-11047 (infusion on Days 1, 8 and 15 of a 28 day cycle) in combination with Erlotinib (150 mg taken orally every day of each 28-day cycle).</description>
        </group>
        <group group_id="B5">
          <title>PG11047/Cisplatin</title>
          <description>Cisplatin: 80 mg/m2 administered IV over 1 hour once every 28 days. PG-11047 will be administered by infusion on Days 1, 8 and 15 of a 28 day cycle.</description>
        </group>
        <group group_id="B6">
          <title>PG11047/5-Flurouracil</title>
          <description>PG-11047 (infusion on Days 1, 8 and 15 of a 28 day cycle) in combination with 5-Flurouracil / Leucovorin (Leucovorin 500 mg/m2 IV over 2 hours with 5 - FU 500 mg/m2 IV bolus starting 1 hour into leucovorin infusion weekly for 6 weeks, repeated every 56 days).</description>
        </group>
        <group group_id="B7">
          <title>PG11047/Sunitinib</title>
          <description>PG-11047 (infusion on Days 1 and 8 of a 21 day cycle) in combination with Sunitinib (50 mg orally once daily, 4 weeks on treatment followed by 2 weeks off (42 day cycle)).</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="34"/>
            <count group_id="B4" value="34"/>
            <count group_id="B5" value="48"/>
            <count group_id="B6" value="32"/>
            <count group_id="B7" value="3"/>
            <count group_id="B8" value="172"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="31"/>
                    <measurement group_id="B6" value="20"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.3" spread="10.8"/>
                    <measurement group_id="B2" value="63.2" spread="13.1"/>
                    <measurement group_id="B3" value="56.3" spread="12.8"/>
                    <measurement group_id="B4" value="62.8" spread="11.0"/>
                    <measurement group_id="B5" value="59.8" spread="10.1"/>
                    <measurement group_id="B6" value="60.2" spread="12.2"/>
                    <measurement group_id="B7" value="60.0" spread="24.4"/>
                    <measurement group_id="B8" value="59.8" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="29"/>
                    <measurement group_id="B6" value="18"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="48"/>
                    <measurement group_id="B6" value="32"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD)</title>
        <description>The MTD was defined as the dose below which one-third of at least 6 patients (2/6) experienced a dose limiting toxicity (DLT).
DLTs had to occur during cycle 1 of treatment and had to be considered related to PG-11047:
Any nonhematologic toxicity &gt; Grade 3 lasting &gt; 3 days
Grade 4 thrombocytopenia
Grade 4 Anemia on the next scheduled dosing day
Grade 4 Neutropenia (lasting &gt; than 5 days
Any febrile neutropenia (Grade 3 or 4))
Inability to receive all scheduled doses of PG-11047 during the first dosing cycle due to drug related toxicity</description>
        <time_frame>End of Study</time_frame>
        <population>Cohorts comprised 3 patients. When a patient experienced a treatment related toxicity qualifying as a DLT, up to 3 additional patients were to be enrolled at that dose. Patients who completed cycle 1 per protocol were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>PG11047/Gemcitabine</title>
            <description>PG-11047 in combination with Gemcitabine</description>
          </group>
          <group group_id="O2">
            <title>PG11047/Docetaxel</title>
            <description>PG-11047 in combination with Docetaxel</description>
          </group>
          <group group_id="O3">
            <title>PG11047/Bevacizumab</title>
            <description>PG-11047 in combination with Bevacizumab</description>
          </group>
          <group group_id="O4">
            <title>PG11047/Erlotinib</title>
            <description>PG-11047 in combination with Erlotinib</description>
          </group>
          <group group_id="O5">
            <title>PG11047/Cisplatin</title>
            <description>Cisplatin: 80 mg/m2 administered IV over 1 hour once every 28 days. PG-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.</description>
          </group>
          <group group_id="O6">
            <title>PG11047/5-Flurouracil</title>
            <description>CGC-11047 in combination with 5-Flurouracil / Leucovorin</description>
          </group>
          <group group_id="O7">
            <title>PG11047/Sunitinib</title>
            <description>PG-11047 in combination with Sunitinib.
The MTD of PG-11047 was undetermineable due to only 2 evaluable patients in this treatment group</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD)</title>
          <description>The MTD was defined as the dose below which one-third of at least 6 patients (2/6) experienced a dose limiting toxicity (DLT).
DLTs had to occur during cycle 1 of treatment and had to be considered related to PG-11047:
Any nonhematologic toxicity &gt; Grade 3 lasting &gt; 3 days
Grade 4 thrombocytopenia
Grade 4 Anemia on the next scheduled dosing day
Grade 4 Neutropenia (lasting &gt; than 5 days
Any febrile neutropenia (Grade 3 or 4))
Inability to receive all scheduled doses of PG-11047 during the first dosing cycle due to drug related toxicity</description>
          <population>Cohorts comprised 3 patients. When a patient experienced a treatment related toxicity qualifying as a DLT, up to 3 additional patients were to be enrolled at that dose. Patients who completed cycle 1 per protocol were evaluable.</population>
          <units>mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="32"/>
                <count group_id="O7" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">MTD not determined due to toxicities leading to study arm being prematurely stopped.</measurement>
                    <measurement group_id="O2" value="NA">MTD not determined due to toxicities leading to study arm being prematurely stopped.</measurement>
                    <measurement group_id="O3" value="590"/>
                    <measurement group_id="O4" value="590"/>
                    <measurement group_id="O5" value="590"/>
                    <measurement group_id="O6" value="590"/>
                    <measurement group_id="O7" value="NA">MTD not determined due to toxicities leading to study arm being prematurely stopped.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Drug Safety</title>
        <time_frame>Ongoing</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics</title>
        <time_frame>End of Study</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PG11047/Gemcitabine</title>
          <description>PG-11047 (infusion on Days 1 and 15 of each cycle) in combination with Gemcitabine (1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle).</description>
        </group>
        <group group_id="E2">
          <title>PG11047/Docetaxel</title>
          <description>PG-11047 (infusion on Day 1 of each 21 day cycle) in combination with Docetaxel (75 mg/m2 administered IV over 60 minutes every 21 days).</description>
        </group>
        <group group_id="E3">
          <title>PG11047/Bevacizumab</title>
          <description>PG-11047 (infusion on Days 1, 8 and 15 of a 28 day cycle) in combination with Bevacizumab (5 mg/kg administered IV once every 14 days).</description>
        </group>
        <group group_id="E4">
          <title>PG11047/Erlotinib</title>
          <description>PG-11047 (infusion on Days 1, 8 and 15 of a 28 day cycle) in combination with Erlotinib (150 mg taken orally every day of each 28-day cycle).</description>
        </group>
        <group group_id="E5">
          <title>PG11047/Cisplatin</title>
          <description>Cisplatin: 80 mg/m2 administered IV over 1 hour once every 28 days. PG-11047 will be administered by infusion on Days 1, 8 and 15 of a 28 day cycle.</description>
        </group>
        <group group_id="E6">
          <title>PG11047/5-Flurouracil</title>
          <description>PG-11047 (infusion on Days 1, 8 and 15 of a 28 day cycle) in combination with 5-Flurouracil / Leucovorin (Leucovorin 500 mg/m2 IV over 2 hours with 5 - FU 500 mg/m2 IV bolus starting 1 hour into leucovorin infusion weekly for 6 weeks, repeated every 56 days).</description>
        </group>
        <group group_id="E7">
          <title>PG11047/Sunitinib</title>
          <description>PG-11047 (infusion on Days 1 and 8 of a 21 day cycle) in combination with Sunitinib (50 mg orally once daily, 4 weeks on treatment followed by 2 weeks off (42 day cycle)).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="48"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>1 not related and 1 related (Docetaxel)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Neutroponic fever</sub_title>
                <description>Not related (1 Docetaxel), related (1 5-FU)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Unlikely related (1 Cisplatin), related (1 Cisplatin)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>Not related (1 Cisplatin), unlikely related (1 5-FU)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <description>Not related (1 Erlotinib and 1Cisplatin)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Volume depletion</sub_title>
                <description>Unlikely related (1 Erlotinib, 2 5-FU)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <description>Unlikely related (Bevacizumab)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Superventricular tachycardia</sub_title>
                <description>Not related (1 Cisplatin), 1 unlikely related (Bevacizumab)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <description>Not related (1 Cisplatin), related (1 Erlotinib)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <description>Not related (2 Erlotinib, 1 Cisplatin), related (1 Cisplatin)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <description>Unlikely related (2 Cisplatin)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <description>Unlikely related (Erlotinib)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>2 not related and 1 unlikely related (Gemcitabine), 2 not related (Bevacizumab),1 related (cisplatin), 1 not related and 1 unlikely related (5-FU)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vomitting</sub_title>
                <description>Not related (2 Gemcitabine, 1 Bevacizumab, 1 5-FU), unlikely related (1 Cisplatin, 2 5-FU), 2 related (Cisplatin)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>1 not related (Gemcitabine) and 1 unlikely related (5-FU)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Right upper quadrant pain</sub_title>
                <description>Not related (Gemcitabine)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Partial bowel obstruction</sub_title>
                <description>Not related (Gemcitabine)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Not related (1 Cisplatin, 1 Bevacizumab, 1 Erlotinib, 1 Cisplatin, 1 5-FU), unlikely related (1 Erlotinib)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Small bowel obstruction</sub_title>
                <description>Not related (3 Bevacizumab, 2 Cisplatin, 2 5-FU), unlikely related (1 Gemcitabine, 1 Erlotinib)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <description>Unlikely related (Cisplatin)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Bowel obstruction</sub_title>
                <description>Not related (1 Cisplatin, 1 5-FU)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>GI bleed</sub_title>
                <description>Unlikely related (5-FU)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Intestinal ileus</sub_title>
                <description>Unlikely related (5-FU)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Ogilvie syndrome</sub_title>
                <description>Not related (5-FU)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <description>Not related (5-FU)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Esophageal ulcers</sub_title>
                <description>Not related (5-FU)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Uncontrolled pain</sub_title>
                <description>Not related (Gemcitabine)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Right lower chest pain</sub_title>
                <description>Not related (Gemcitabine)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <description>Unlikely related (Bevacizumab)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <description>2 not related and 1 unlikely related (Cisplatin)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Unresponsive</sub_title>
                <description>Not related (Cisplatin)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Not related (Cisplatin)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <description>Unlikely related (Cisplatin)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <description>Not related (1 Erlotinib, 1 Cisplatin, 1 5-FU)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <description>Not related (Cisplatin)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <description>Not related (Cisplatin)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Biliary obstruction</sub_title>
                <description>Not related (Cisplatin)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity allergic reaction</sub_title>
                <description>Not related (Cisplatin)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteremia</sub_title>
                <description>1 not related (Gemcitabine), unlikely related (1 Gemcitabine, 1 5-FU)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <description>1 not related and 1 unlikely related (Bevacizumab)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC</sub_title>
                <description>Not related (Bevacizumab)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>Unlikely related (2 5-FU), related (5-FU)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated creatinine</sub_title>
                <description>Related (Cisplatin)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Elevated bilirubin</sub_title>
                <description>Not related (1 Erlotinib, 1 Cisplatin)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>2 unlikely related (Gemcitabine), 2 not related (Bevacizumab), 1 not related and 1 related (Erlotinib), 1 not related and 1 related (Cisplatin), 3 unlikely related (5-FU)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <description>Not related (Cisplatin)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <description>Not related (Cisplatin)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <description>Unlikely related (5-FU)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <description>Not related (5-FU)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain right hip</sub_title>
                <description>Not related (Bevacizumab)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <description>Not related (Erlotinib)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <description>Not related (2 Gemcitabine, 3 Bevacizumab, 2 Erlotinib, 4 Cisplatin, 5 5-FU)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Metastatic rectal cancer</sub_title>
                <description>Not related (Erlotinib)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered mental status</sub_title>
                <description>1 unlikely related (Gemcitabine), 1 not related (Erlotinib), 1 not related (Cisplatin)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <description>Not related and unlikely related (Cisplatin)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Not related (Cisplatin)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Increased confusion</sub_title>
                <description>Not related (1 Cisplatin, 1 5-FU)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <description>Not related (1 Cisplatin and 1 5-FU)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Acute CVA</sub_title>
                <description>Not related (5-FU)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hemorrhage CNS</sub_title>
                <description>Related (Sunitinib)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <description>Not related (2 Erlotinib, 2 Cisplatin), unlikely related (1 Cisplatin, 2 5-FU), related (1 Erlotinib, 2 Cisplatin)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Ureteral obstruction</sub_title>
                <description>Not related (Cisplatin)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>Not related (2 Erlotinib, 1 Cisplatin, 1 5-FU), related (1 Bevacizumab, 1 Cisplatin)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <description>Not related (2 5-FU), unlikely related (2 Bevacizumab)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <description>Unlikely related (Cisplatin)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <description>Not related (1 Cisplatin, 1 5-FU)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <description>Not related (2 Cisplatin, 2 5-FU), unlikely related (1 Erlotinib)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <description>Not related (5-FU)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <description>Related (2 Erlotinib)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Oversedation</sub_title>
                <description>Not related (Cisplatin)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Tracheostomy</sub_title>
                <description>Not related (Cisplatin)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Post operative trachea hemorrhage</sub_title>
                <description>Not related (Cisplatin)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vain thrombosis</sub_title>
                <description>Not related (1 Docetaxel), related (1 Cisplatin)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Unlikely related (5-FU)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="48"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="32"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="16" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="12" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E6" events="7" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="12" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E5" events="9" subjects_affected="8" subjects_at_risk="48"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="16" subjects_affected="9" subjects_at_risk="48"/>
                <counts group_id="E6" events="4" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="7" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E5" events="14" subjects_affected="12" subjects_at_risk="48"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="9" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E5" events="18" subjects_affected="11" subjects_at_risk="48"/>
                <counts group_id="E6" events="11" subjects_affected="8" subjects_at_risk="32"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="4" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="4" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Central line infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="12" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="7" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E6" events="7" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Blood amylase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E5" events="9" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoaesthesia facial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="6" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Trials</name_or_title>
      <organization>Progen Pharmaceuticals Pty Ltd</organization>
      <phone>+61 7 32739133</phone>
      <email>darrynb@progen-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

